文献速递类风湿关节炎

已确诊类风湿关节炎患者启动生物制剂治疗后的疲劳轨迹

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy.
PubMed 文献 · RMD Open · 2020-01-01

多数患者可归为无疲劳、疲劳改善或持续疲劳三种轨迹之一,持续疲劳与患者报告结局相关,而非炎症指标。

要点

  • 启动生物制剂治疗的RA患者中,持续疲劳轨迹与患者报告结局相关,而非炎症活动指标。
  • 持续疲劳组更常见ACPA和/或RF阳性,基线PROMs更高。
  • 患者整体评估、压痛关节数和焦虑是持续疲劳轨迹的预测因素。

核心结论

  • 持续疲劳轨迹由患者报告结局决定,而非炎症性RA疾病活动度。

研究设计与样本

  • 疲劳用RAID问卷中的疲劳NRS(0-10)评估,临床显著疲劳预设为≥4。
  • 定义三种轨迹:无疲劳(5/6次访视≤3)、疲劳改善(起始≥4但随访≤3)、持续疲劳(5/6次访视≥4)。

主要发现

  • 多数患者归入三种轨迹:无疲劳n=61、改善n=33、持续疲劳n=53。
  • 持续疲劳组更可能ACPA和/或RF阳性,基线PROMs更高,但炎症变量组间无差异。
  • 患者整体评估、压痛关节数和焦虑是持续疲劳轨迹的预测因素。

关键数值与推荐

  • 临床显著疲劳预设为疲劳NRS≥4。
  • 无疲劳轨迹:5/6次访视疲劳≤3。
  • 改善轨迹:起始疲劳≥4但随访≤3。
  • 持续疲劳轨迹:5/6次访视疲劳≥4。

临床怎么用

  • 对启动bDMARD的RA患者应关注疲劳轨迹,持续疲劳者需评估患者报告结局和心理因素而非仅控制炎症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To define fatigue trajectories in patients with rheumatoid arthritis (RA) who initiate biological DMARD (bDMARD) treatment, and explore baseline predictors for a trajectory of continued fatigue. METHODS: One-hundred and eighty-four patients with RA initiating bDMARDs were assessed at 0, 1, 2, 3, 6 and 12 months. Swollen and tender joint counts, patient reported outcomes (PROMs), blood samples and ultrasound examinations were collected at each time point. Fatigue was assessed by the fatigue Numeric Rating Scale (0-10) from the Rheumatoid Arthritis Impact of Disease (RAID) questionnaire. Clinically significant fatigue was predefined as fatigue ≥4. Three trajectories of interest were defined according to level of RAID fatigue: no fatigue (≤3 at 5/6 visits), improved fatigue (≥4 at start, but ≤3 at follow-up) and continued fatigue (≥4 at 5/6 visits). Baseline variables were compared between groups by bivariate analyses, and logistic regression models were used to explore baseline predictors of continued vs improved fatigue. RESULTS: The majority of patients starting bDMARD therapy followed one of three fatigue trajectories, (no fatigue; n=61, improved; n=33 and continued fatigue; n=53). Patients with continued fatigue were more likely to be anti-citrullinated protein antibody and/or rheumatoid factor positive and had higher baseline PROMs compared to the other groups, while there were no differences between the groups for variables of inflammation including. Patient global, tender joint count and anxiety were predictors for the continued fatigue trajectory. DISCUSSION: A trajectory of continued fatigue was determined by PROMs and not by inflammatory RA disease activity.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Provan SA, Michelsen B, Sexton J, et al. Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy. RMD Open. 2020. PMID: 33214326. doi:10.1136/rmdopen-2020-001372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。